IL21R and inflammatory bowel disease: Studies have shown that IL-21R activation can inhibit Th1 and activate Th2, Th17, and Treg responses, which can help alleviate DSS-induced acute colitis, and IL-21R may be a new target for the treatment of inflammatory bowel disease and other enterodynamic disorders (Ian et al., 2007; Wang et al., 2016).